NCT06882564 Efficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.
| NCT ID | NCT06882564 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Al-Mustansiriyah University |
| Condition | Halitosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2025-01-05 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 54 participants in total. It began in 2025-01-05 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study: To assess the efficacy of antioxidant (resveratrol) mouthwash in reducing the level of p. gingivitis and oral malodor over 7 day period among undergraduate dental student patients from Mustansiriyah University/College of Dentistry and Wasit University /College of Dentistry. Objectives: * To assess the efficacy of anti-oxidant and anti-inflammatory resveratrol mouthwash in reducing halitosis in undergraduate students with plaque-induced gingivitis patients. * To assess the efficacy of resveratrol mouthwash in reducing p. gingivalis in undergraduate students' patients with oral malodor. * To determine the relation between p.gingivalis and clinical periodontal parameters (plaque index, gingival index, bleeding on probing) among undergraduate students with plaque-induced gingivitis and halitosis.
Eligibility Criteria
Inclusion Criteria: * Organoleptic tongue of scores \> 2 using (0-5scale) (Rosenberg and McCulloch, 1992) * Male and female undergraduate dental students without chemical plaque control measures for at least one weak * Male and female students with halitosis due to gingivitis * The age of students ranges from 20 to 23 years. * No periodontal treatment for at least one month * No systemic disease * No tobacco smoking * The patients must have at least 20 teeth Exclusion Criteria: * Smokers and alcoholics * Patient with periodontitis or pocket depth \> 6mm * Patient with orthodontics appliance * Open carious lesions, pericoronitis, dry socket, and fistula. * Patients with systemic disease and condition * taking medication in the last two weeks * Take garlic, onion, or licorice in the last 24 hours * using oral hygiene products in the last 24 hours * pregnant women * sinusitis, tonsilitis, and upper respiratory tract infection
Contact & Investigator
NOOR AA TAHER, B.D.S
PRINCIPAL INVESTIGATOR
Al-Mustansiriyah University
Frequently Asked Questions
Who can join the NCT06882564 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 24 Years, studying Halitosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06882564 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 54 participants.
Is NCT06882564 currently recruiting?
Yes, NCT06882564 is actively recruiting participants. Contact the research team at noor-aliabed@uomustansiriyah.edu.iq for enrollment information.
Where is the NCT06882564 trial being conducted?
This trial is being conducted at Baghdad, Iraq.
Who is sponsoring the NCT06882564 clinical trial?
NCT06882564 is sponsored by Al-Mustansiriyah University. The principal investigator is NOOR AA TAHER, B.D.S at Al-Mustansiriyah University. The trial plans to enroll 54 participants.